The cure, or even just an effective treatment, for Alzheimer's disease has remained elusive for decades. Many pharmaceutical companies to date have jumped on the bandwagon for targeting beta amyloid plaques after they develop. Unfortunately, no matter how promising drugs appear in phase 2 results, they fail in phase 3 trials without slowing the progression of this debilitating neurological disease. Now, researchers at the University of Cambridge have discovered the mechanism for the formation of beta amyloid plaques. Can this discovery lead to an effective treatment? It certainly has potential, but developing antibodies to target the process will take many years. Get the details from Fool contributor Maxx Chatsko in the video below.
Will Eli Lilly be the first to treat Alzheimer's?
The pharmaceutical company has attempted to develop treatments for the disease for over two decades -- to no avail. With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more click here to claim your copy today.
The article Is This the Beginning of the End for Alzheimer's? originally appeared on Fool.com.
Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and emerging technologies.The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.